Transgenic Mouse, ICSI & IVF Core

项目摘要/摘要-转基因小鼠、ICSI和试管受精核心 在动物体内导入外源基因或选择性地敲除内源基因的能力是 对基础和临床研究具有极其重要的意义。特别是，随着CRISPR/CA的出现 随着科技的发展，体内基因调控出现了前所未有的机会。因此，转基因是一种 非常强大的工具，有助于体内基因组编辑和转录调节，对解剖必不可少 转录、信号和环境对疾病遗传基础的影响 开发新的治疗干预策略。此外，小鼠配子操纵、克隆 技术、干细胞来源和培养是许多成功的关键技术 研究机构，特别是那些专注于生殖和发育生物学的机构。 在第一阶段，夏威夷大学转基因小鼠，ICSI和体外受精核心(TMII)在研究所 生物发生研究已经建立，并取得了重大进展，朝着成为 在十五年内独立支持，积累了大量用于微操作的设备 该中心还负责小鼠配子和胚胎培养，并招募了经验丰富的研究人员为Core实验室工作。 第二阶段的资金加强并将科布雷中心发展成为一个最先进的设施，拥有 在提供高效和经济的转基因动物及其相关资源方面的杰出记录 技术，包括CRISPR技术。这些服务提供给科布雷大学的教职员工 夏威夷的研究人员和全国各地的科学家。核心继续开发新基因 传递技术，包括在靶向基因插入方面取得重大进展。 此第三阶段Cobre应用程序的目标是增强核心并将其转变为自我 持续的资源实体。除了扩展我们的核心服务外，我们还将继续努力改善 这些服务的质量和提供以及加强和精简核心业务。核心还将 加强其外联工作，并将重点放在教育和培训上，以此作为获取新的 大学级别的客户。我们将通过协调和协调我们的 核心资源和服务与分子和细胞免疫学(MCI)核心的资源和服务相同。我们的目标还包括 通过增加和多样化调查队伍来加强核心收入基础，利用其众多 供品。具体地说，我们将扩大我们的外展范围，改善营销活动，并探索机会 与其他Cobre、INBRE和IDEA-CTR机构的核心合作。

PROJECT SUMMARY/ABSTRACT – Transgenic Mouse, ICSI and IVF Core The ability to introduce foreign genes or to selectively knock out endogenous genes in animals is of tremendous importance for basic and clinical research. In particular, with the advent of CRISPR/Cas technology, unprecedented opportunities for in vivo gene modulations have arisen. As such, transgenesis is a very powerful tool facilitating in vivo genome editing and transcription modulation, essential to dissect transcriptional, signaling, and environmental influences on the genetic basis of diseases but also for the development of novel therapeutic intervention strategies. Furthermore, mouse gamete manipulation, cloning technology, stem cell derivation, and -culture are a series of techniques that are essential for many successful research institutes in particular those with a focus on reproductive and developmental biology. During Phase I, the University of Hawaii Transgenic Mouse, ICSI and IVF Core (TMII) at the Institute for Biogenesis Research was established and made significant progress towards the goal of becoming independently supported within fifteen years, accumulated a large array of equipment for micromanipulation of mouse gametes and embryo culture and recruited experienced researchers to staff the Core laboratory. Funding during Phase II strengthened and developed the COBRE Center into a state-of-the-art facility with an outstanding track record in providing efficient and economic access to transgenic animals and related technologies, including CRISPR technologies. The services were provided to COBRE faculty, University of Hawaii researchers and scientists around the country. The Core continued the development of novel gene delivery technology, including making significant progress on targeted gene insertion. The objective of this Phase III COBRE application is to enhance and transform the Core into a self- sustained resource entity. Besides expanding our Core services, we will continue to work on improving the quality and delivery of these services and on enhancing and streamlining core operations. The Core will also enhance its outreach and focus on education and training as principal conduits for the acquisition of new customers at the University level. We will diversify our existing portfolio by coordinating and harmonizing our Core resources and services with those of the Molecular and Cellular Immunology (MCI) Core. We also aim to strengthen the core revenue base by increasing and diversify the contingent of investigators utilizing its many offerings. Specifically, we will expand our outreach, improve marketing activities and explore opportunities for collaborations with cores from other COBRE, INBRE and IDeA-CTR institutions.